Virginia Oncology Associates
The Bruton Tyrosine Kinase (BTK) Inhibitor Ibrutinib Promotes a High Frequency of Durable Response in Relapsed/ Refractory and Older Treatment-Naïve CLL.
R System. Lymphadenectomy pelvic para-aortic no Lymphadenectomy epithelial invasive ovarian cancer FIGO IIB - IV ECOG 0/1 and no CI against LNE no visible.
Efficacy of BSI-201, a PARP Inhibitor, in Combination with Gemcitabine/Carboplatin in Triple Negative Metastatic Breast Cancer: Results of a Phase II Study.
OVARIAN CANCER COMMITTEE Phillipp Harter / Christian Marth
Comparison of Mutations and Protein Expression in Potentially Actionable Targets in 5500 Triple Negative vs. non-Triple Negative Breast Cancers Joyce A.
Enfermedad Triple Negativa: ¿hacia dónde vamos?
Med fusion Site Management Organization (SMO) Making Clinical Trials More Efficient 1.
